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Background: Health-related quality of life (HRQoL) is a rapidly growing area of expertise
and themost commonly used patient-reported outcome (PRO).The impact of cystic ﬁbrosis
(CF) on HRQoL is liable to be great, making CF patients ideal candidates for the application
of HRQoL instruments.The aims of this studywere to assess the affect of CF on HRQoL, to
ascertain the reliability and validity of the United Kingdom Sickness Impact Proﬁle (UKSIP)
and the Cystic Fibrosis Quality of Life Questionnaire (CFQoL) in the adult CF population, and
to examine their role in the management of patients. Methods: Seventy participants were
recruited from the AllWales Adult Cystic Fibrosis Centre at Llandough Hospital, UK.There
were two stages to the study: self-report of the UKSIP and CFQoL; and completion of the
same twoquestionnaires 7–10 days later.Results:The areas ofHRQoLmost impaired byCF
were employment and concerns regarding the future.The UKSIP and CFQoL showed high
internal consistency (rα= 0.89–0.93) and test–retest reliability (r s = 0.57–0.94, p< 0.005)
in the CF population. Validity was variable with the UKSIP showing discrimination across
socio-demographic factors, whilst the CFQoL showed increased sensitivity to clinical vari-
ables. Many parameters inﬂuenced patient-reported HRQoL, with the greatest correlations
seen with the Borg score (p< 0.005).The use of a HRQoL instrument in CF annual reviews
is recommended to provide holistic patient care.The results of this study underpin the value
of HRQoL as a patient-reported outcome measure in the management of adult CF.
Keywords: cystic fibrosis, quality of life, health-related quality of life, cystic fibrosis quality of life questionnaire,
United Kingdom sickness impact profile
INTRODUCTION
Cystic ﬁbrosis (CF) is the most common genetic disease in Cau-
casians (Sheppard and Nicholson, 2002). The outlook for CF
patients has greatly improved over recent years and the life
expectancy of a child born in the 2000s is predicted to be in excess
of 40 years, double that of 20 years ago (Mason, 2005). The impact
of CF on a patient’s Health-related quality of life (HRQoL) is
likely to be great and cannot be assessed purely by physiological
parameters, and therefore analysis of patient’s views on the wider
impact of the disease is needed (Fallowﬁeld, 1991). The nature of
CF results in an increase in treatment burden, yet a decrease in
physical and psychosocial health over time. This, complimentary
to the fact that there is considerable variation in disease sever-
ity, makes CF patients ideal candidates for application of HRQoL
instruments. QoL is also increasingly being recognized by major
CF organizations as a priority area of investigation (WHO, 1999;
Littlewood, 2001), to establish its relevance as a patient-reported
outcomes (PROs) measure in the management of CF.
Quality of life research in CF patients has primarily focused on
assessment of speciﬁc treatments, comparison with other popula-
tions, and comparison with some clinical variables (Hatziagorou
et al., 2002). Wahl et al. (2005) commented that “little attention
has been paid to patient satisfaction with broader life domains.”
This study addresses this gap in research, and prioritizes areas of
importance to the patient that may not have been predicted by
the physician. Assessment in this area focuses on the patient and
their needs; an invaluable resource for practitioners to develop a
partnership of care with the patient, following the current think-
ing at the forefront of healthcare policy (Marshall et al., 2005).
Analysis of present literature also identiﬁed a skewed coverage of
QoL favoring adolescents with CF over adults (Jong et al., 1997a).
As a demographic change toward an increasing number of adults
with CF has taken place, this study focused on an adult population
(WHO, 1999).
Hatziagorou et al. (2002) comment that much needs to be done
to improve the quality of QoL measures. This study provides sig-
niﬁcant information about the suitability of the United Kingdom
Sickness Impact Proﬁle (UKSIP) and Cystic Fibrosis Quality of
Life questionnaire (CFQoL; Gee et al., 2000; Quittner et al., 2009)
as instruments to assess HRQoL in CF patients; by assessing their
validity, reliability, and patient acceptability. The UKSIP is a gold
standard generic questionnaire that has previously never beenused
in a CF population, and the CFQoL is a disease-speciﬁc ques-
tionnaire that has never been validated against a gold standard
HRQoL instrument. Using this unique and highly comprehensive
double-instrument technique also allows areas of HRQoL to be
highlighted that may have been overlooked in previous studies
using individual instruments.
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MATERIALS AND METHODS
STUDY PARTICIPANTS
The sample population was recruited from the Specialist Adult
Centre for CF at Llandough Hospital, Cardiff over a 10-week
period. Participantswere over 16 years old, in a stable phase of their
disease and had adequate understanding to complete the question-
naires. There were three separate cohorts recruited: outpatients;
inpatients; and postal respondents.
STUDY INSTRUMENTS
A double-instrument technique was used, including generic and
disease-speciﬁc measures. This approach is highly favored as it is
both robust and clinically advantageous (French, 1995; Bowling,
2002; Fitzpatrick, 2002). Before considering different applications
of patient-based outcome measures, it is helpful to note a recom-
mendation that has been made by some authors that the optimal
strategy is to use a combination of types of measure in a clini-
cal trial. Most commonly it is recommended that trialists include
a generic together with a disease-speciﬁc measure (Guyatt et al.,
1991; Fletcher et al., 1992; Bombardier et al., 1995; Abbott et al.,
2011). The main argument for such an approach is that the two
kinds of measures are likely to produce complementary evidence
in showing change over time (Fitzpatrick et al., 1998).
THE UNITED KINGDOM SICKNESS IMPACT PROFILE
The UKSIP is the British version of the American SIP developed
in the early 1970s. It is a self-reported, tick box, weighted instru-
ment consisting of 12 different categories: sleep and rest; eating;
work; home management; recreation and pastimes; ambulation;
mobility; body care and movement; social interaction; alertness
behavior; emotional behavior; and communication (Schraufnagel,
1999). Scores are derived from a weighted scale, with increasing
score indicating a greater impairment of HRQoL. The SIP has
been shown to be of use in the chronically ill (Bowling, 2005),
and its speciﬁc use in CF has also been demonstrated (Jong et al.,
1997a). The UKSIP has the advantage of generating a single index
score, summary indices and proﬁle scores for the 12 categories.
The UKSIP has an established validity and reliability in many dis-
ease areas (Salek and Luscombe, 1992), and has also been used
as a generic HRQoL measure in a number of chronic conditions
such as atopic dermatitis (Sowden et al., 1991; Salek et al., 1993a),
acne (Salek et al., 1996), psoriasis (Salek et al., 2004), renal (Salek
et al., 2003), Parkinson’s disease (Salek et al., 1993b, 1994), car-
diovascular (Salek and VandenBurg, 1988), and arthritis (Salek,
1997).
CYSTIC FIBROSIS QUALITY OF LIFE QUESTIONNAIRE
TheCFQoL is a patient-derived self-reported instrument designed
speciﬁcally to assess the needs of CF patients (Gee et al., 2000). It
covers nine areas: physical functioning; social functioning; treat-
ment issues; chest symptoms; emotional functioning; concerns
for the future; interpersonal relationships; body image; and career
concerns (Gee et al., 2003). It has a six-point Likert scale where the
degree of agreement or frequency of occurrence is given a numer-
ical value; with a decreasing score indicating a greater impairment
on QoL. It has high reliability and validity, and robust discrimina-
tory ability (Gee et al., 2000). This credibility coupled with its ease
of use (about 10min to complete and of UK origin) means that
it has been utilized in several trials for CF (Gee et al., 2003, 2005;
Esmond et al., 2006).
The CFQoL was selected for this study following careful exami-
nation of a number of QoL instruments such as the Cystic Fibrosis
Questionnaire (CFQ14+; Henry et al., 2003) developed in France,
Living with Cystic Fibrosis Questionnaire (LCFQ; Patterson et al.,
2008) developed in the USA and EuroQol 5 Dimension for Chil-
dren andAdolescents (EQ-5D-Y;Wille and Ravens-Sieberer, 2006;
Wille et al., 2006a,b). Consequently, the CFQoL was considered to
be the most robust, widely used and cross culturally translated CF
speciﬁc QoL instrument (Debska and Mazurek, 2007; Monti et al.,
2008).
STUDY DESIGN
There were two stages to the study: the ﬁrst stage (Test I) involved
completion of the two questionnaires when delivered by the inter-
viewer or received by post; the second stage (Test II) was comple-
tion of the same two questionnaires 7–10 days later, with a postal
return.
The outpatients were recruited from the weekly CF clinics at
Llandough hospital. The consultant assessed the stability of the
patients’ health before recruitment to provide validation of the
test–retest reliability analysis. This was achieved by ensuring all
participants had no signiﬁcant change in lung function (within
10% of their normal FEV1).
The inpatients were recruited on the day of discharge from hos-
pital and were asked to complete the UKSIP whilst the researcher
was present. The CFQoL was not completed at this stage due to its
retrospective frame of reference. The remaining three question-
naires were then supplied to the participant to return by post.
A separate cohort of patients not scheduled to attend clinic
within 10weeks was identiﬁed. These 54 patients were sent the
entire study by post. These participants were coded separately.
The three cohorts were included in the study in order to capture
different degrees of severity and to secure a bigger sample size.
All participants were provided with self-addressed stamped
envelopes to return the second stage, as well as covering letters
specifying the dates of completion. To minimize training effect,
order of the completion of the questionnaires was randomized for
the outpatient and postal cohorts using computer generated ran-
dom numbers. Those who did not respond in the postal cohort
were contacted ﬁrst by telephone and then by letter. If there was
no subsequent response then they were classed as non-responders.
All clinical data was collected from the notes on the day of
completionof the questionnaire or if thiswas unavailable, from the
next closest date. This included data on lung function (FEV1, FVC,
and PEFR) and nutritional adequacy (body mass index, BMI), as
well as the use of oral and enteral supplementary feeds. Physical
activity was assessed using the Borg score; an established known
measure of the perception of dyspnea, and consequently exercise
capacity in CF (Dodd et al., 2005; Debska and Mazurek, 2007).
DATA ANALYSIS
The data was not normally distributed and therefore was analyzed
by descriptive and non-parametric tests using SPSS 18.0. The use
of Mann–Whitney U tests established no signiﬁcant difference
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between the mean scores of the postal and interviewer-delivered
cohorts, therefore they were analyzed as one sample.
Differences in scoreswere analyzedwith the socio-demographic
and clinical status of the participants using Mann–Whitney U
Tests. Associations between the HRQoL scores and the socio-
demographic and clinical measures were examined using Spear-
man’s rank correlation coefﬁcients. Reliability was assessed by
internal consistency (Cronbach’s alpha) and test–retest reliabil-
ity analysis (Spearman’s rank correlation coefﬁcients). These are
the standard reliability tests used to assess HRQoL instruments.
Validity of the instruments was considered by concurrent, predic-
tive, and face validity. The signiﬁcance level was set at p< 0.05
for two tailed tests. All correlations were interpreted according to
the guidelines set by Cohen in 1988, small (r =±0.10 to 0.29),
medium (r =±0.30 to 0.49), and large (r =± 0.50 to 1.0; Pallant,
2005).
RESULTS
SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE
STUDY PARTICIPANTS
A total of 118 patients were recruited into the study of whom 70
took part (Table 1); an overall response rate of 59%. The patients
mean age was 26 (median= 23; range 17–61 years) with 45 (64%)
males (Table 2). Thirty-nine (56%) of the study participants were
unemployed. Over half the study population reported that CF had
stopped them working at some point, with 82% of those cur-
rently unemployed attributing it to their CF. Thirty-four (69%) of
those participants responding had completed college education,
with just three of the participants having only completed primary
education. Clinical data is displayed in Table 1.
Table 3 shows the nutritional and lung function values of the
study participants. As the scores were not normally distributed,
both the mean and median have been reported as well as the
ranges seen.
Table 4 highlights the mean HRQoL scores; showing that the
poorest area on HRQoL was work for the UKSIP (M = 31.8) and
concerns for the future in the CFQoL (M = 49.2).
RELATIONSHIP BETWEEN HRQoL SCORES AND SOCIO-DEMOGRAPHICS
Moderate correlations were found between age and the patient-
reported UKSIP categories recreation and pastimes (r s = 0.35,
p = 0.003) and work (r s = 0.31, p = 0.01), as well as small cor-
relations with overall score, ambulation and home management
(r s = 0.25–0.29, p< 0.05). No correlations between the CFQoL
scores and age were found.
Females reported a poorer HRQoL than males in all UKSIP
categories except for communication, where males showed the
Table 1 |The UKSIP and CFQOL response rates.
Response rates Overall
Interviewer
administered
Postal
First stage 92% (n=59/64) 20% (n=11/54) 59% (n=70/118)
Second stage 58% (n=34/59) 36% (n=4/11) 54% (n=38/70)
greatest impairment (p = 0.38). A statistically signiﬁcant poorer
HRQoL was seen for females in the UKSIP categories, emotional
behavior (p = 0.012) and eating (p = 0.033). No signiﬁcant differ-
ences in CFQoL scores were found between males and females.
Gender differences were not examined in detail as this has already
been researched in the present literature (Gee et al., 2005).
Participants’ employment status resulted in differences in
UKSIP scores in all areas except communication (p< 0.05), with
the unemployed reporting a poorer HRQoL. Highly signiﬁcant
differences were found between employed and unemployed par-
ticipants for all CFQoL domains except treatment issues and
concerns for the future (p< 0.01).
Signiﬁcant differences were found between those at secondary
and college education levels in the UKSIP categories ambulation,
alertness behavior, work, and physical dimension (p< 0.01); with
Table 2 | Socio-demographic characteristics of the study participants.
Age (n=70)
Mean (±SD) 26.1 (±7.3)
Median 23.5
Range 17–61
Gender (n=70)
Male (%) 64.3
Female (%) 35.7
Education (n=49)
Primary (%) 6.1
Secondary (%) 24.5
College (%) 69.4
Employment (n=70)
Employed (%) 44.3
Unemployed (%) 55.7
Date of birth (n=70)
Mode 1986
Range 1944–1988
Diagnosis (n=63)
Year diagnosed
Mode 1986
Range 1965–2004
Age diagnosed (years)
Mean (±SD) 3 (±9)
Median 0
Range 0–60
Time since diagnosis (years)
Mean (±SD) 24 (±8)
Median 23
Range 2–41
Table 3 | Clinical characteristics of the study participants.
Mean (±SD) Median (range)
BMI 22.4 (±3.9) 21.7 (16–38)
FEV1 (% pred) 66.4 (±25.1) 67.0 (21–120)
FVC (% pred) 84.4 (±22.1) 85.0 (27–125)
PEFR(% pred) 76.1 (±18.8) 78.0 (28–127)
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Table 4 | Mean and median HRQoL scores as measured by the UKSIP
(n =70) and the CFQoL (n =70).
CF patients Healthy
population
Mean
(±SD)
Median
(range)
Mean
(±SD)
UKSIP CATEGORY*
Overall score 9.4 (9.9) 6.6 (0–43.7) 2.07 (3.36)
Physical dimension 4.7 (7.1) 1.6 (0–34.0) 0.76 (2.25)
Body care and movement 2.9 (5.9) 0.0 (0–32.9) 0.48 (2.27)
Mobility 5.6 (10.4) 0.0 (0–45.3) 0.94 (3.60)
Ambulation 5.5 (8.2) 0.0 (0–30.9) 1.26 (4.30)
Psychosocial dimension 7.8 (10.9) 2.5 (0–57.2) 2.90 (5.90)
Emotional behavior 9.8 (16.8) 0.0 (0–100.0) 3.30 (8.09)
Social interaction 9.0 (11.5) 5.8 (0–50.1) 3.93 (7.15)
Alertness behavior 8.4 (14.1) 0.0 (0–56.6) 3.00 (10.17)
Communication 4.1 (9.3) 0.0 (0–42.8) 0.35 (2.44)
Independent categories
Sleep and rest 13.4 (18.2) 9.8 (0–87.8) 3.37 (6.30)
Home management 8.90 (15.6) 0.0 (0–63.0) 1.26 (4.38)
Work 31.8 (33.0) 13.8 (0–70.1) 4.04 (13.11)
Recreation and pastimes 10.2 (17.2) 0.0 (0–86.0) 5.33 (11.25)
Eating 3.0 (7.1) 0.0 (0–49.5) 0.78 (2.62)
CFQoL DOMAIN**
Physical functioning 77.6 (22.7) 86.0 (14.0–100)
Social functioning 79.9 (24.2) 90.0 (0–100)
Treatment issues 71.5 (27.5) 80.0 (0–100)
Chest symptoms 74.5 (26.1) 85.0 (0–100)
Emotional functioning 79.7 (23.3) 87.5 (7.5–100)
Concerns for the future 49.2 (26.6) 46.7 (0–100)
Interpersonal relationships 65.2 (26.0) 69.0 (0–100)
Body image 67.1 (27.8) 66.7 (0–100)
Career concerns 59.9 (31.6) 62.5 (0–100)
Total score 70.2 (19.6) 73.9 (16.5–100)
*Increasing score indicating a greater impairment on HRQoL and improvement
with decreasing scores.
**Decreasing score indicating a greater impairment on HRQoL and improvement
with increasing scores.
the former showing the greater impairment on HRQoL. Signiﬁ-
cant differences were also found with overall UKSIP score, body
care and movement, mobility and eating (p< 0.05). There were
no signiﬁcant differences with the study participants in the pri-
mary education group. One signiﬁcant difference was found in
the CFQoL categories across education, with those completing
primary education showing an increased impairment on HRQoL
in the career concerns than those in college education (p< 0.05).
RELIABILITY OF THE UKSIP AND CFQoL
The standard level for acceptability of Cronbach’s alpha values
is >0.70. The internal consistency reliability of the UKSIP and
CFQoL was high for both Test I and Test II; with Cronbach’s
alpha coefﬁcients of 0.87 and 0.90 (n = 70 and 38), and 0.90 and
0.93 (n = 57 and 30), respectively. Test–retest reliability for both
instruments was high; UKSIP (r s = 0.57–0.84, p< 0.01, n = 38)
and CFQoL (r s = 0.74–0.94, p< 0.01, n = 38) demonstrating an
acceptable level of reproducibility for both measures.
VALIDITY
Face validity
All participants found the CFQoL easy to understand (n = 68)
and easy to complete (n = 68). Fifty-two participants (74%) were
willing to complete it every time they came to clinic (n = 67), and
completion time was approximately 9min.
Concurrent validity
All categories except communication in the UKSIP showed sig-
niﬁcant correlations with the UKSIP patient-rated overall health
question (r s = 0.26–0.55, p< 0.05). Similarly the CFQoL scores
were signiﬁcantly correlated in all domains except concerns for
the future (r s =−0.27 to−0.69,p< 0.05). Similar domains (emo-
tion, social interaction, physical, employment, and total scores)
in the two questionnaires showed highly signiﬁcant correlations
(r s =−0.50 to −0.76, p< 0.01).
PREDICTIVE VALIDITY
Disease severity
Disease severity was deﬁned according to FEV1 (% predicted) as
mild (≥70%), moderate (40–69%), and severe (<40%); n = 32,
25, and 11 respectively. No signiﬁcant differences were found
between UKSIP scores for severe and moderate disease. Signiﬁcant
differences in UKSIP scores between moderate and mild disease
severities were found for ambulation, work, physical dimension,
and overall score (p< 0.05). Severe disease showed the larger
impairment on HRQoL than mild disease in the UKSIP cate-
gories physical dimension (p = 0.01) and eating (p< 0.05), as
well as work, ambulation and overall UKSIP score (p< 0.05).
Two highly signiﬁcant differences were found between the severe
and mild disease severities for the CFQoL categories chest symp-
toms (p< 0.01) and body image (p< 0.01). Signiﬁcant differences
were also found between severe and mild disease severities for the
CFQoL categories physical functioning, chest symptoms, emo-
tional functioning, body image, career concerns, and total score
(p< 0.05). The severe disease groups also showed a greater impair-
ment on emotional functioning than the moderate severity group
(p< 0.05). Differences were also found between moderate and
mild disease severities in physical functioning (p< 0.05) and chest
symptoms (p< 0.05).
Body mass index. No signiﬁcant differences were found between
theUKSIP scores andBMI classiﬁcations (≤19 (underweight), 20–
29 (normal), ≥30 (overweight), n = 11, 53, and 5 respectively. In
the CFQoL scores the underweight participants reported a poorer
physical functioning (p< 0.05) and body image (p< 0.01) than
those in the normal group. They also reported a poorer HRQoL
compared to the overweight group across physical functioning,
treatment issues, body image, and career concerns (p< 0.05).
Between the normal and overweight groups signiﬁcant differ-
ences were found for treatment issues (p< 0.05) and career con-
cerns (p< 0.05), with the greatest impairment in the normal
group.
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Supplementary feeding. A highly signiﬁcant difference was
found between oral supplementary feeding and enteral feeding
groups in relation to theUKSIP categories sleep and rest (p< 0.01)
and eating (p< 0.05). In theCFQoL scores, a highly signiﬁcant dif-
ference was found across body image with those receiving enteral
feeding reporting a poorer HRQoL than those not receiving any
form of supplementary feeding (p< 0.01). Those receiving oral
supplements reported an increased impairment on HRQoL in
treatment issues (p< 0.05) and body image (p< 0.005).
The BORG scale. The Borg score showed highly signiﬁcant cor-
relations (p< 0.01) with 12 of the UKSIP categories, nine of
these showed large correlations (r s = 0.50–0.61).With the CFQoL,
correlations were found in all domains except treatment issues,
eight domains were statistically signiﬁcant (r s =−0.39 to −0.62,
p< 0.05).
DISCUSSION
This studyhas found thatCFhas a substantial impact onHRQoL in
relation towork and concerns regarding the future. The percentage
of unemployed in this study is comparable to recent survey statis-
tics, where 53% were currently unemployed (Walters and Warren,
2001). Consideration of the large effects observed on HRQoL due
to unemployment, in parallel to the fact that over three quarters
of those unemployed reported CF as the cause, highlights that CF
has a direct substantial impact on this domain of life. The nega-
tive implications of unemployment on HRQoL is a well reported
phenomenon; both generally (Fallowﬁeld, 1991; Scrambler, 1995)
and speciﬁcally with regards to CF (Harris and Super, 1995; Jong
et al., 1997a). Therefore a healthcare professional’s role in pro-
viding employment advice, with regards to health, could be key
to improving HRQoL in this area. The increasing future concerns
relating to fertility and transplant status are likely to cause HRQoL
impairment in young adults, and as they progress through adult-
hood the prospect of an early death becomes more of a reality.
This highlights a need in clinical practice for the role of counsel-
ing and psychology in a multidisciplinary approach to CF care,
as has already been recommended in current guidelines (Kerem
et al., 2005).
This study has also revealed that dyspnea could have a large
impact on a CF patient’s HRQoL, as the Borg score correlated
more signiﬁcantly than any other clinical variable. This is con-
sistent with other studies that have found that dyspnea is highly
correlated to HRQoL, indicating the considerable effect that it has
on the patient’s life (Schrier et al., 1990; Jong et al., 1997b). One
theory of why dyspnea is so closely related to HRQoL scores is that
the questions used in assessing physical HRQoL and the dyspnea
value are similar, containing the samequestions to assess both areas
(e.g., Are you feeling breathless?; Schrier et al., 1990). In contrast,
the ﬁndings in this study showHRQoL impairment acrossmany of
the categories in both questionnaires. Because of the relatively new
use of the Borg score at Llandough Hospital not all patients had
received an assessment, reducing the sample population involved.
However the fact that such large statistical signiﬁcance was shown
indicates that this is an area that merits further investigation. The
greater correlations seen with the UKSIP suggest that it may be the
broader domains of HRQoL that are inﬂuenced by dyspnea.
The greater impairment seen on HRQoL with increasing age
(using the UKSIP) is to be expected, due to the multiple patholog-
ical conditions that a CF patient faces as their disease progresses,
and is reported in current literature (Quittner et al., 2005). How-
ever, the CFQoL did not show correlations with age, perhaps
suggesting a lack of speciﬁcity of the CFQoL.
The UKSIP results, suggesting that women have a statistically
lowerHRQoL concerning emotional wellbeing thanmen, comple-
ment thepresent literature (Congleton et al.,1996;Gee et al.,2003).
The decreased HRQoL with regards to eating in females compared
to men is reported elsewhere (Abbott et al., 2000), and suggests a
differing attitude between males and females in relation to food
and can be linked to the increased likelihood of eating disorders
seen in women (Walters, 2001). Males reported a poorer HRQoL
in the CFQoL body image domain, a ﬁnding previously reported
(Abbott et al., 2000;Gee et al., 2003). This could be explainedby the
fact that the low BMI often seen in CF patients may be considered
undesirable to males but more appealing to women in relation to
their ideal personal body type, irrespective of the health implica-
tions. The poorer overall HRQoL indicated in women compared
to men may be because women are subject to a poorer prognosis
than males in CF (Harris and Super, 1995;Abbott et al., 2000). The
CFQoL did not detect any signiﬁcant differences between males
and females, which could indicate a lack of discriminative ability
in this area; contrary to its use in other papers (Gee et al., 2003;
Gobbi et al., 2005).
The physical dimension in the UKSIP was most affected by
disease severity; this is as expected as a poorer lung function
would limit physical activities. The CFQoL supports this with the
greatest difference being shown in chest symptoms. Eating was
also adversely affected highlighting the other major pathological
effect of CF which is on the gastrointestinal system, where 95%
of patients show exocrine pancreatic insufﬁciency with symptoms
of malabsorption and constipation (Mason, 2005). No signiﬁcant
differences were found between the severe and moderate disease
severities in the UKSIP and only one in the CFQoL, suggesting
that HRQoL reduces signiﬁcantly once a patient reaches mod-
erate disease severity. However, it could be that neither of the
instruments were sensitive enough to detect differences between
these two disease groups, as other questionnaires in literature have
demonstrated discriminatory ability in this area (Quittner et al.,
2005).
The UKSIP showed no discrimination between the groupings
by BMI, implicating the superiority of the CFQoL with regards to
relationships with clinicalmeasures. The fact that the underweight
reported a poorer HRQoL again highlights the major impact that
the failure to thrive caused by CF has on the HRQoL of the
individual. Physical functioning was reduced in the underweight
participants suggesting theyhave apoorer overall health andphysi-
cal capacity. Thismaybe becausemalnutrition is linked in a vicious
circle to lung infection (Ratjen and Doring, 2003).
TheUKSIP highlighted an impairment on sleep relatedHRQoL
of those receiving enteral feeding, probably due to the fact that
the feeds are usually given overnight (Mason, 2005). This is a
very important issue as adequate sleep is regarded as a prime
requirement to the QoL of any person (Salek, 1993). Body image
in the CFQoL was also reduced in the enteral feeding group,
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possibly due to an increased self consciousness (Abbott et al.,
1999). Those on oral supplements reported problems in the treat-
ment issues domain suggesting that adding another dimension
of treatment can impair a patient’s HRQoL. This could be of
increased relevance in CF due to the polypharmacy involved
and the compliance issues that patients are continually faced
with. This could have clinical practice implications when weigh-
ing up the beneﬁt risk ratio of adding a treatment to a patient’s
regimen.
Both Test I and Test II alpha coefﬁcients for the UKSIP and
CFQoL were high, indicating their acceptable internal consistency
reliability in this application. The reliability values for the CFQoL
complement the current literature and were greater than those for
the UKSIP (Gee et al., 2000). Not all participants replied within
the 7- to 10-day period speciﬁed, however this would only reduce
the correlation seen between the scores meaning that the reli-
ability reported is probably lower than reality. The UKSIP has
demonstrated good reliability and validity as a proxy assessment
by informed carers (i.e., husbands, wives, siblings, etc.; Salek et al.,
1995a,b,c). However, this was not examined in this study since it
is not relevant to the CF population.
Face validity of the CFQoL was high, however some of the
comments from the participants highlighted the need for a not
applicable option on the questionnaire. The UKSIP also had some
patient comments regarding the fact that there was no sometimes
option, and some participants found the wording hard to under-
stand, reducing its face validity. The response rate in this study
was slightly above average (Walters and Warren, 2001; Gee et al.,
2003). However, the UKSIP was developed as a generic measure
for use in patients with different diseases andwas extensively tested
for its psychometric properties and showed excellent content and
discriminant validity (Bergner et al., 1981).
Concurrent validity with the UKSIP was established through
a strong association with the patient-rated overall health ques-
tion. The fact that concerns for the future was not correlated is
likely to be because the impairment in this domain is so great
that it is not related to their present state of health but is contin-
ual throughout their life. This is backed by ﬁndings in another
study that found poor scores for this domain irrespective of dis-
ease severity (Walters and Warren, 2001). The questionnaires also
showed high correlations between their applicable domains, again
indicating that they are both adequately measuring HRQoL. This
validity complements the present literature for the CFQoL which
has shown good concurrent validity with the SF-36 (Gee et al.,
2000).
Predictive validity and sensitivity of the questionnaires was
variable. The UKSIP was highly discriminative across socio-
demographic areas with limited clinical distinction; and the oppo-
site was true of the CFQoL.Accurate choice of a generic or disease-
speciﬁc measure could therefore be fundamental when these ques-
tionnaires are used in research or clinical practice. Although not
examined in this study, both instruments have shown to be capable
of detecting change over time (Salek et al., 1993a). The number of
assessment points in detecting change over time depends on the
aims and objective of the study, but should not be used at assess-
ment points of less than 4-week intervals to avoid under or over
estimation.
LIMITATIONS
One limitation of this study was that there was a mixture of postal
return and interviewer-administered questionnaires. Although
this could be a potential source of bias, it is common practice
to use a postal method to ensure practicality for the patient, and
was essential to ensure that patients who did not attend clinic
were included in the results. A further limitation is that many
statistical tests were completed, increasing the likelihood of signif-
icant results due to chance. This was confounded by the fact that
more than one factor could inﬂuence HRQoL, for example the
results were not adjusted for age or gender when looking at disease
severity. However, as there were few erratic or inexplicable results
and high levels of clinical signiﬁcance reported, this limitation is
reduced. Finally, the differing protocols required for inpatients,
outpatients, and postal cohorts could cause bias; however these
were designed to limit their affect on the results.
CONCLUSION
The role of HRQoLmeasures as a PROcanoffer“a newdimension”
to multidisciplinary health care and complement clinical practice
by the inclusion of a HRQoL measure in a CF annual review set-
ting (Salek, 1993; Gee et al., 2000). This approach was identiﬁed as
being beneﬁcial by a participant who commented that they wished
they could have completed a similar questionnaire earlier in their
disease process to compare it with their results now. Increased
consideration of HRQoL issues when considering clinical inter-
ventions and treatments is also important in the management of
patients with CF.
This study highlights the detrimental impact that unemploy-
ment has on all areas of HRQoL. However, the inﬂuence of CF on
working status goes beyond personal health status, to involve com-
plicated and possibly sensitive issues surrounding social stigma
and discrimination. Several participants mentioned problems
gaining and maintaining employment that they attributed to their
CF; resulting in some not revealing their CF to employers. These
issues may also inﬂuence the patient’s perspective on whether they
are ﬁt to work which could have substantial implications on clin-
ical practice with regards to: treatments that could facilitate CF
patients to return to work; encouragement and explanation of the
health beneﬁts of working by health care professionals; and advice
to patients during periods of unemployment.
Until recently no CF speciﬁc HRQoL measures were available,
therefore assessment in this area is fairly novel. Despite their indi-
vidual limitations, the two instruments used in this study offer
reliability and validity in the CF population. As the life expectancy
of theCFpopulation continues to increase, theuse of HRQoLmea-
sures should rise in accordance with this; both tomaximize patient
beneﬁt and to allow effective partnership between the healthcare
professional and the CF patient. The use of two questionnaires in a
clinical setting is impractical, but the importance of assessment of
both speciﬁc and broader domains was identiﬁed as paramount.
With this in mind, creation of a HRQoL instrument for CF incor-
porating both the generic and speciﬁc inﬂuences recognized in
this study, whilst maintaining the reliability and validity of the
two instruments used, is recommended for enhancing the role of
patient-reported outcomes in the management of patients with
CF. In the meantime, clinicians are encouraged to use the most
Frontiers in Pharmacology | Pharmaceutical Medicine and Outcomes Research March 2012 | Volume 3 | Article 38 | 6
Salek et al. PROs in CF patient management
relevant UKSIP domains (i.e., emotional behavior, social interac-
tion, sleep and rest, work, recreation, and pastimes) and CFQOL
domains (i.e., concerns for the future, independent relationships,
body image, and career concerns) in their routine clinical setting.
This approach of course could be at the expense of compromised
reliability and validity of the measures.
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